DE Burlo Group Inc. Buys 630 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

DE Burlo Group Inc. increased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 49,195 shares of the pharmaceutical company’s stock after purchasing an additional 630 shares during the period. Vertex Pharmaceuticals makes up approximately 2.8% of DE Burlo Group Inc.’s portfolio, making the stock its 12th biggest holding. DE Burlo Group Inc.’s holdings in Vertex Pharmaceuticals were worth $22,880,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Jennison Associates LLC increased its position in shares of Vertex Pharmaceuticals by 18.1% in the third quarter. Jennison Associates LLC now owns 5,550,386 shares of the pharmaceutical company’s stock worth $2,581,373,000 after purchasing an additional 851,054 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Vertex Pharmaceuticals by 5.8% in the third quarter. Massachusetts Financial Services Co. MA now owns 2,905,705 shares of the pharmaceutical company’s stock worth $1,351,385,000 after buying an additional 159,693 shares in the last quarter. Janus Henderson Group PLC boosted its stake in Vertex Pharmaceuticals by 10.4% in the first quarter. Janus Henderson Group PLC now owns 2,584,315 shares of the pharmaceutical company’s stock worth $1,080,296,000 after buying an additional 244,336 shares in the last quarter. Legal & General Group Plc boosted its stake in Vertex Pharmaceuticals by 1.2% in the second quarter. Legal & General Group Plc now owns 2,422,677 shares of the pharmaceutical company’s stock worth $1,135,556,000 after buying an additional 29,104 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. boosted its stake in Vertex Pharmaceuticals by 1.0% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 672,098 shares of the pharmaceutical company’s stock worth $312,579,000 after buying an additional 6,716 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors.

Insider Activity

In other Vertex Pharmaceuticals news, Director Sangeeta N. Bhatia sold 646 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $500.00, for a total value of $323,000.00. Following the sale, the director now owns 4,435 shares of the company’s stock, valued at $2,217,500. The trade was a 12.71 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Chairman Jeffrey M. Leiden sold 3,784 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $499.00, for a total value of $1,888,216.00. Following the transaction, the chairman now directly owns 9,994 shares in the company, valued at approximately $4,987,006. This represents a 27.46 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 4,445 shares of company stock valued at $2,218,394 in the last ninety days. Corporate insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ:VRTX opened at $451.23 on Thursday. Vertex Pharmaceuticals Incorporated has a 1-year low of $346.29 and a 1-year high of $519.88. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. The business has a fifty day moving average price of $475.38 and a 200-day moving average price of $472.74.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating the consensus estimate of $3.61 by $0.77. The company had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. Vertex Pharmaceuticals’s revenue was up 11.6% compared to the same quarter last year. During the same period last year, the firm posted $3.67 earnings per share. As a group, analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.82 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on VRTX shares. UBS Group upped their target price on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Raymond James reaffirmed a “market perform” rating on shares of Vertex Pharmaceuticals in a research note on Thursday, October 10th. Morgan Stanley upped their target price on Vertex Pharmaceuticals from $473.00 to $476.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. Cantor Fitzgerald reissued an “overweight” rating and set a $480.00 price objective on shares of Vertex Pharmaceuticals in a research note on Tuesday, November 5th. Finally, Bank of America dropped their price objective on Vertex Pharmaceuticals from $550.00 to $541.00 and set a “buy” rating for the company in a research note on Monday, October 14th. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $499.12.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.